The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area
about
Continuous positive airway pressure (CPAP) for acute bronchiolitis in childrenContinuous positive airway pressure (CPAP) for acute bronchiolitis in childrenNebulised deoxyribonuclease for viral bronchiolitis in children younger than 24 monthsNebulised deoxyribonuclease for viral bronchiolitis in infantsModelling estimates of the burden of respiratory syncytial virus infection in children in the UKHypertonic saline (HS) for acute bronchiolitis: Systematic review and meta-analysisDefining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Infants with Chronic Lung DiseaseDefining the Epidemiology and Burden of Severe Respiratory Syncytial Virus Infection Among Infants and Children in Western CountriesDefining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart DiseaseGlobal burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysisRespiratory Syncytial Virus Hospitalizations in Healthy Preterm Infants: Systematic Review.Evaluation of recent New Vaccine Surveillance Network data regarding respiratory syncytial virus hospitalization rates in US preterm infantsModern approaches to understanding stress and disease susceptibility: A review with special emphasis on respiratory diseaseCosts of hospitalization with respiratory syncytial virus illness among children aged <5 years and the financial impact on households in Bangladesh, 2010.Risk factors for hospital admission with RSV bronchiolitis in England: a population-based birth cohort study.Palivizumab for preterm infants. Is it worth it?Acute bronchiolitis in a paediatric emergency department of Northern Greece. Comparisons between two decades.Acute bronchiolitisNon-invasive respiratory support for infants with bronchiolitis: a national survey of practice.Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phasRespiratory Syncytial Virus Related Readmission in Preterm Infants Less than 34 weeks' Gestation Following Discharge from a Neonatal Intensive Care Unit in Korea.Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.Admission to hospital for bronchiolitis in England: trends over five decades, geographical variation and association with perinatal characteristics and subsequent asthma.Innate and adaptive immune response to pneumonia virus of mice in a resistant and a susceptible mouse strain.A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom.Management of acute viral bronchiolitis in children: Evidence beyond guidelines.Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV)Prospective Multicentre Study on the Epidemiology and Current Therapeutic Management of Severe Bronchiolitis in SpainClinical predictors of nasal continuous positive airway pressure requirement in acute bronchiolitis.Respiratory syncytial virus--a comprehensive review.Preventing severe respiratory syncytial virus disease: passive, active immunisation and new antivirals.Recent advances in the management of acute bronchiolitis.Where are we with RSV prophylaxis?Modulation of Host Immunity by Human Respiratory Syncytial Virus Virulence Factors: A Synergic Inhibition of Both Innate and Adaptive Immunity.Infants under 6 months with bronchiolitis are most likely to need major medical interventions in the 5 days after onset.Hepatitis during respiratory syncytial virus infection--a case reportDevelopment and validation of the Liverpool infant bronchiolitis severity score: a research protocol.Question 2: Will continuous positive airway pressure reduce the need for ventilation in bronchiolitis?Improved clinical and economic outcomes in severe bronchiolitis with pre-emptive nCPAP ventilatory strategy.Assessing efficient patient care: should length of stay be calculated independently of local admission rates?
P2860
Q24186710-1F8CA588-CC60-46AB-B77A-7B14DBAC1EADQ24198079-54D844AC-1195-4485-B038-436B4CDBA20AQ24202863-9A800D3A-4A57-4533-AB89-B43BACA62B53Q24239887-FA9A8150-D9F8-4504-93A6-457A5C320FD2Q24658528-05ED6948-6438-45E5-BA83-C05738BA6E04Q26776447-12857628-DAC1-429F-947B-6127E3934FBFQ28067464-A2F510A5-7B86-44D7-878A-61F7CF0E7A71Q28069415-E205037D-53E6-42A6-B7C4-8BCE096B84B0Q28072535-EB515EC2-39B4-4660-8C94-F3C1E249EDA7Q29619821-EB80EAD3-F8B7-46E8-9A85-8613227540D9Q30251560-501D9D22-1EAC-4F3A-A634-7E1EF495C81EQ31047460-735CB0D7-82C6-477E-BF2E-20DCB207D0CDQ33735083-0675E00A-CA18-4990-A652-A4E0923471CFQ33887198-68AB41E4-04CA-4E35-A1EB-B74A8302C742Q35106819-16AC600F-EBFF-4007-AF21-27DA863E4136Q35296973-0D923E15-6900-4F12-94A8-A7156F92F78BQ36105673-CC3C30FB-4D36-48E7-AD1D-BDF176A9E645Q36145677-39A0DB37-DD6E-48E3-9353-90CF2F08BEC6Q36251831-A69A1AB8-675F-4D6D-88E0-23D2EE03A7C3Q36258838-819A9E57-3EB5-4A03-AD39-D9EC1AB95C1EQ36269402-0F2B8659-A843-4975-AFB5-3601A5300D6CQ36347381-82C73F68-82AE-4947-9AAE-A1B22619D747Q36577321-23F45412-261B-4264-B397-DE004623D3C2Q36586894-BDCE8081-9176-4705-98BD-57420042CA48Q37075484-C730CB4F-0A47-4B1E-843F-5487FD955F7DQ37105886-01622D79-B403-4E0F-B48E-2E23A184583AQ37290618-D4387D83-4D1A-498A-A5CB-C5A5DC9DEC8BQ37737715-69E4D62A-81D1-47AC-8753-D0D195121E48Q37929095-A7CCDC5E-7E10-415A-B78D-651D940AB06EQ38098094-92DD4D5B-BAD4-4AFC-904B-23E40B5DFCD8Q38182054-4262132E-3E58-4783-A39D-E758402F2E4CQ38314877-90FFEB07-44AD-441B-A85D-79B9E70095B1Q38385728-D15C36F0-EBFE-4248-ACD1-A09F2B872800Q40061831-9F4724A2-A08A-493D-8C43-52B91FC8BCB9Q40205925-1D58A1E0-EB44-498B-85E9-305615D8FDCBQ41887681-CE8C19B4-E8F4-469D-A63E-5337F0A06ABEQ42221991-D251BAF8-01C3-4A6E-BD84-95A514DEE752Q42240845-3CE939A0-8FB2-495A-B0E2-2733B94593F7Q42259905-B0BC13FB-5717-4DC2-ADE5-595FD3A41641Q43700026-5BD2F2D6-C9C3-4987-AB46-EF3EA43110C7
P2860
The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area
description
2003 nî lūn-bûn
@nan
2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The clinical and health econom ...... in a defined geographical area
@ast
The clinical and health econom ...... in a defined geographical area
@en
type
label
The clinical and health econom ...... in a defined geographical area
@ast
The clinical and health econom ...... in a defined geographical area
@en
prefLabel
The clinical and health econom ...... in a defined geographical area
@ast
The clinical and health econom ...... in a defined geographical area
@en
P2860
P356
P1476
The clinical and health econom ...... in a defined geographical area
@en
P2093
Deshpande SA
Northern V
P2860
P304
P356
10.1136/ADC.88.12.1065
P407
P577
2003-12-01T00:00:00Z